ClinicalTrials.gg
Active, not recruitingNCT06675552PHRASE-HFUpdated Aug 20, 2026

Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany

An observational study in Heart Disease, Heart Failure and Cardiovascular Disease, sponsored by AstraZeneca. Active, not recruiting at 6 sites in Germany. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Primary conditionHeart Failure, SystolicRegistry: Heart DiseasesReclassifiedWhy we changed it
Registry
Heart Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure, Systolic
Why
  1. The study's listed conditions name Heart Failure, Systolic, a narrower term within Heart Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
338
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure, Systolic with a site in Germany — 2 open to participants now, 3 under way, none of them phase 3. Heart Failure, Systolic · Germany.

Started
2024
the only one that year
Observational
3 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
AstraZeneca

Among the 11 studies in Heart Failure, Systolic with a site in Germany, this one is the only one that started in 2024, is one of 3 observational ones, and was the 11th registered.

Heart Failure, Systolic

230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.

Browse Heart Failure, Systolic studies →

Open to participants now

2 of the 11 studies in Heart Failure, Systolic with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 28 Heart Failure, Systolic studies recruiting now, 18 (64%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure, Systolic with a site in Germany, or all of them as a file.
02

Study summary

Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial. Heart failure with reduced ejection fraction (HFrEF) represents approximately 50% of the HF patient population.The burden of HF is expected to increase substantially as the population ages, and despite improvements in treatment, hospitalisation and mortality rates remain especially high in HFrEF patients. The current guideline recommendation of directed medical therapy for HFrEF combines four drug classes with proven prognostic benefit: Angiotensin receptor-neprilysin inhibitor (ARNI)/angiotensin converting enzyme inhibitors (ACE I)/angiotensin receptor blockers (ARB), betablockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i). The 2023 ESC (European Society of Cardiology) HF guideline update additionally recommends a rapid in-hospital sequencing approach of guideline-directed medical therapy (GDMT) with frequent physician visits during the first 6 weeks post discharge. Studies investigating the implementation of GDMT in a real-world setting have shown that a significant proportion of patients did not receive the recommended drug combination therapy. Delayed initiation of GDMT contributes to the low number of patients receiving guideline concordant HFrEF therapy, which ultimately may affect patient outcomes. One approach to implement the 2023 ESC guideline updates for heart failure treatment regarding early in-hospital initiation and rapid up-titration of GDMT could be to provide specific training on GDMT recommendations. Such a standardised training is offered to the physicians treating HF patients within selected hospitals of the German Helios hospital network (Helios-GDMT-program). Evidence is needed in order to assess whether in-hospital initiation and up-titration of all phenotype concordant classes of GDMT at hospital discharge can be observed after standardised physician training and whether the GDMT-program implementation also translates into real-world routine outpatient care with respect to use of GDMT and clinical outcomes.

Read the detailed description

The overall aim of PHRASE-HF is to evaluate the use of GDMT at hospital discharge, the translation of in-hospital implementation and possible maximisation of phenotype-based GDMT into real-world routine outpatient care, HF symptoms, patient reported outcomes (PROs), clinically relevant outcomes (e.g. rehospitalisation, mortality), use of diuretics and concomitant drug classes in patients admitted for in-hospital treatment of HFrEF to sites trained within the Helios-GDMT-program. The analyses will primarily be done in a total study population, and as defined by exploratory objectives in subgroups of interest.

03

Conditions studied

  • Heart Disease
  • Heart Failure
  • Cardiovascular Disease
  • Heart Failure, Systolic

Keywords

  • Heart Failure with Reduced Ejection Fraction (HFrEF)
  • Guideline Directed Medical Therapy
  • Real-World Evidence
04

In context

Heart Failure, Systolic Reclassified

230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.

This study's enrollment of 338 is above the median of 250 across 54 observational studies indexed under Heart Failure, Systolic.

Browse Heart Failure, Systolic studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.

Compared within Heart Failure, Systolic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Approximately 438 patients with reduced ejection fraction (HFrEF) admitted for in-hospital treatment with a maximum of 2 of the indicated guideline recommended drug classes (ACE-I/ARNI/ARB, BB, MRA, SGLT2i) in the current medication plan are planned to be enrolled consecutively. Recruitment will take place at 5-7 inpatient cardiology departments at Helios hospitals trained by Helios-GDMT-Program throughout Germany.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of signing the
  • Hospitalised in a participating site and receiving full inpatient treatment (at least 24h hospital stay)
  • Diagnosis of HFrEF according to the current guidelines of the European Society of Cardiology (ESC) with a left ventricular EF of ≤40% (as measured per echocardiography during the index hospital stay or within 3 months prior to index hospitalisation with available reports from imaging () at the time of study inclusion)
  • Treated with a maximum of 2 of the indicated drug classes (ACE-I/ARNI/ARB, BB, MRA, SGLT2i) according to guideline recommendation (GDMT) at admission.
  • Signed and dated written informed consent prior to enrolment in the study
  • Willing and capable to fulfil requirements listed in the ICF

Exclusion criteria

Exclusion Criteria:

  • Initial presentation (index hospitalisation) in cardiogenic shock or other kinds of shock
  • Status post heart transplantation
  • History of intolerance to one or more GDMT drug classes (ACE-I/ARNI/ARB, BB, MRA, SGLT2i) or significant side effects that led to the discontinuation of two or more substances within one drug class (except from ACE-I/ARB, e.g., if 2 different ACE inhibitors triggered cough, but sartans are tolerated, then the patient is not excluded)
  • Current or planned participation in a clinical trial
  • Decision by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures
  • Pregnancy or breast-feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
338 participants (actual)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Proportion of patients treated with HFrEF GDMT

    Proportion of patients treated with phenotype-concordant guideline-recommended HF drug classes and the corresponding doses as noted in patients electronic medical records

    Time frame: Baseline to hospital discharge, on average 6 days after hospitalization/baseline

Secondary outcomes

  1. Number of recommended HF-drug classes

    The HF-drug classes including the corresponding doses that are recommended in discharge letter at hospital discharge

    Time frame: Baseline to hospital discharge, on average 6 days after hospitalization/baseline

  2. Change of percentage in HFrEF GDMT

    The percentage of patients who are newly initiated on guideline-directed HFrEF medical therapy

    Time frame: Baseline to 12 months

  3. Change of phenotype-concordant guideline-recommended HF drug classes

    The number of patients with change in phenotype-concordant guideline- recommended HF drug classes

    Time frame: Hospital Discharge (on average 6 days after hospitalization/baseline) to 12 months

  4. Reasons for GDMT adjustments

    The reasons for guideline-directed medical therapy changes as noted in patients electronic medical records will be described as the number and proportion of patients who experienced adjustment in guideline-directed medical therapy according to each reasons presented

    Time frame: Hospital Discharge (on average 6 days after hospitalization/baseline) to 12 months

  5. Reasons for not having guideline-recommended drug classes or doses

    The reasons for not having maximal phenotype-concordant guideline-recommended HF drug classes as noted in patients electronic medical records will be described as the number and proportion of patients who are not having maximal GDMT drug classes according to each reasons presented

    Time frame: Hospital Discharge (on average 6 days after hospitalization/baseline) to 12 months

  6. Number of outpatient post-discharge visits

    The number of outpatient visits for heart failure treatment within the first three months after hospital discharge

    Time frame: Hospital Discharge (on average 6 days after hospitalization/baseline) to 3 months

  7. Proportion of patients conducting post-discharge visits

    Proportion of patients conducting post-discharge visits for heart failure treatment within the first three months after hospital discharge

    Time frame: Hospital Discharge (on average 6 days after hospitalization/baseline) to 3 months

  8. Absolute change from baseline in NYHA class

    The NYHA classification is a regimen for the classification of heart failure into certain stages according to clearly defined criteria. Treatment of heart failure is usually based on the NYHA classification. Symptoms used to evaluate the stages include dyspnea, nocturia at night, cyanosis, general weakness and fatigue, angina pectoris or cold extremities, edema. NYHA-I: No limitation on resilience. Complete absence of symptoms or signs of exertion when heart disease is diagnosed; NYHA-II: Slight decrease in endurance. Freedom from discomfort during rest and with mild exertion, occurrence of symptoms with increased stress; NYHA-III: Severe limitation of resilience. Freedom from discomfort at rest, occurrence of symptoms even with mild exertion; NYHA-IV: Permanent symptoms, even during rest.

    Time frame: Measured at 6 and 12 months

  9. Change from Baseline in blood pressure

    Changes in patients blood pressure as noted in patients electronic medical records /

    Time frame: Baseline to 12 months

  10. Change from Baseline in heart rate

    Changes in patients heart rate as noted in patients electronic medical records

    Time frame: Baseline to 12 months

  11. Change from Baseline in electrolyte level

    Changes in patients electrolyte level as noted in patients electronic medical records

    Time frame: Baseline to 12 months

  12. Change from Baseline in potassium level

    Changes in patients potassium level as noted in patients electronic medical records

    Time frame: Baseline to 12 months

  13. Change from Baseline in estimated glomerular filtrations rate

    Changes in patients estimated glomerular filtration rate as noted in patients electronic medical records

    Time frame: Baseline to 12 months

  14. Change from Baseline in serum creatinine concentration

    Changes in patients serum creatinine concentration as noted in patients electronic medical records

    Time frame: Baseline to 12 months

  15. Number of rehospitalization for heart failure

    The number of patients being rehospitalized for heart failure within the observational period

    Time frame: Hospital Discharge (on average 6 days after hospitalization/baseline) to 12 months

  16. Overall Survival

    Number of patients who died during the observational period

    Time frame: Baseline to 12 months

  17. CV-specific survival

    Number of patients who died due to cardiovascular disease during observation period

    Time frame: Baseline to 12 months

  18. Absolute change from baseline in Medication Adherence Report Scale (MARS)-5 questionnaire

    The MARS-5 is five-item self-report adherence scale which assesses both intentional and non-intentional non-adherence. Respondents rate the frequency with which the five different medication-taking behaviours occur, scoring each item on a 1-5-point scale with higher scores indicating higher reported adherence. The MARS-5 has been shown to be reliable and valid across a variety of health conditions, including cardiovascular and pulmonary diseases. Only applicable to Prospective cohort.

    Time frame: Measured at 6 and 12 months

  19. Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    The KCCQ is a 23-item questionnaire that quantifies physical limitations, self-efficacy, social interference and quality of life. Summary scores will be examined at each assessment point during follow-up. For each of the assessment periods, descriptive statistics for the observed value, change from baseline and the 95% two-sided confidence interval for the mean change will be presented. The proportions of participants with overall health status classified as poor, fair, good, and excellent will be examined at each assessment point. Additionally, the proportions of participants who experience clinically meaningful changes in overall health status: improvement (≥5 point increase), deterioration (≥5 point decrease), and stable (\<5 point increase or decrease) will be examined at each assessment point. Only applicable to Prospective cohort

    Time frame: Measured at 6 and 12 months

  20. Absolute change from baseline in PROMIS Global Health 10

    The PROMIS 10 is a validated comprehensive and accessible set of tools used to measure self-reported physical, mental and social health; including symptoms, function and general perceptions of health and wellbeing. The PROMIS 10 consists of ten items that measure physical health, physical functioning, general mental health, emotional distress, satisfaction with social activities and relationships, ability to carry out usual social activities and roles, pain, fatigue and overall quality of life.

    Time frame: Measured at 6 and 12 months

  21. Absolute change from baseline in the Nine-Item Patient Health Questionnaire (PHQ-9)

    HF is associated with depressive disorders and manifest depressions. The PHQ-9 that capture depressed mood and anhedonia has been validated as an ultra-brief screening tool with some evidence of responsiveness. The PHQ-9 score is obtained by adding the score for each question (total points). A PHQ-9 score ranges from 0-27, to determine whether they meet criteria for a depressive disorder.

    Time frame: Measured at 6 and 12 months

  22. Number of diuretics changes

    The number of patients who experience a switch in their diuretic medication drug class as noted in patients electronic medical record

    Time frame: Baseline to 12 months

  23. Number of concomitant medication changes

    The number of patients who experience a switch in their concomitant medication drug class as noted in patients electronic medical record

    Time frame: Baseline to 12 months

08

Study locations

6 sites
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Erfurt, 99089, Germany
  • Research Site
    Gifhorn, 38518, Germany
  • Research Site
    Leipzig, 04289, Germany
  • Research Site
    Schwerin, 19049, Germany
  • Research Site
    Wuppertal, 42117, Germany
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm/ST/Submission/Disclosure

Access criteria: When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm/ST/Submission/Disclosure

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

Of 27 observational studies under Heart Failure, Systolic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 53. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Nov 5, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06675552
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Nov 15, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion